La cadena de opciones muestra datos clave de las opciones de acciones de Allarity Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Allarity Therapeutics..

Allarity Therapeutics (NASDAQ:ALLR) Bolsa, Cadena de Opciones

Allarity Therapeutics

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

Tesla Rival XPeng Eyes $13.8 Billion Investment In Humanoid Robots, Says Chinese State Media

Equities

Market Summary

News

Pre-Market Outlook

Markets

Trading Ideas

ALLR

NCNO

SPWH

ULBI

XPEV

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: ULBI, XPEV, NCNO, ALLR y SPWH.

5 acciones en el foco este martes: ULBI, XPEV, NCNO, ALLR y SPWH

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics Inc

Allreal Holding Ltd

Benchmark analyst Cody Acree maintains Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Buy and lowers the price target from $230 to $200.

Price Target

Analyst Ratings

Benchmark Maintains Buy on Texas Instruments, Lowers Price Target to $200

WIIM

HCSG

Healthcare Services Group shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target on the stock from $12 to $15. Additionally, Baird raised its price target from $12 to $13.

Bank Of America Securities analyst Andrew Obin maintained a Buy rating on 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) with a price forecast of $170 following <a href="https://www.benzinga.com/quote/MMM/analyst-ratings" target="_blank" rel="noreferrer noopener">first-quarter results reported on Tuesday</a>.
The company reported net sales of&nbsp;$5.95 billion, a decline of&nbsp;1.0%&nbsp;year-over-year (Y/Y), beating the consensus of&nbsp;$5.781 billion, and adjusted EPS was&nbsp;$1.88, up 10%&nbsp;Y/Y,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44921668/3m-stock-surges-after-q1-beat-as-2025-outlook-flags-tariff-pressure" rel="noreferrer noopener">beating the consensus of&nbsp;$1.77</a>.
3M sees 2025 adjusted EPS of $7.60-$7.90 (vs. cons. $7.75) and additional tariff sensitivity losses to 20 to 40 cents <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">per share</a>.
The analyst writes that the company&#8217;s results beat expectations, with strength noted in electrical markets, industrial adhesives and tapes (Safety &amp; Industrials), aerospace (Transportation &amp; Electronics), and consumer safety and well-being (Consumer).
The analyst notes that 3M estimates a total annualized tariff impact of $850 million. Still, due to the April start date and their 90-day inventory cycle, the company expects a $400 million effect before offsets in 2025.
The analyst believes the impact of Chinese import tariffs is more heavily concentrated in its consumer business.
Obin reiterated the 2025 EPS estimate at $7.60, factoring in a 40-cent headwind from tariffs (an increased $0.20 impact).
This negative effect is negated by an additional 16-cent benefit from foreign exchange (as FX assumptions are less unfavorable than 3M&#8217;s guidance), and the 10-cent operational beat in the first quarter adds the analyst.
The analyst projects a 6-cent headwind in the second through fourth quarters due to the timing of interest expenses.
Investors can gain exposure to GLW via&nbsp;ProShares Smart Materials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TINT#NYSE">TINT</a>) and&nbsp;Invesco Exchange-Traded Fund Trust II Invesco S&amp;P Ultra Dividend Revenue ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDIV#NYSE">RDIV</a>).
Price Action: 3M shares are up 1.89% at $138.63 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44944368/us-stocks-likely-to-open-higher-after-trump-administration-hints-at-a-deal-with-china-it-is-prudent-to-expect-continued-volatility-in-the-weeks-ahead-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Higher After Trump Administration Hints At A Deal With China: &#8216;It Is Prudent To Expect Continued Volatility In The Weeks Ahead,&#8217; Says Expert</a></li>
</ul>
Image: Shutterstock

Large Cap

Reiteration

RDIV

TINT

3M Navigates Tariffs, Analyst Expects Headwinds Due To Interest Expenses

CVLG

Covenant Logistics Group shares are trading higher. The company reported Q1 financial results.

Ki Young Ju, Founder and CEO of on-chain analytics platform CryptoQuant, says he's open to conceding a major forecast error, if Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44380265/bitcoin-is-past-the-bull-cycle-peak-top-analyst-warns">breaks above $100,000.</a>
What Happened: In a <a href="https://x.com/ki_young_ju/status/1915001569638256692">post </a>on X (formerly Twitter), Ju acknowledged that Bitcoin is now trading 10% higher than when he recently declared the bull cycle to be over.
Despite the move, he remains cautious, stating, "If it breaks above $100K, I'll gladly admit I was wrong."
Ju's recent comments on X follow his earlier analysis, which flagged a potential market top based on historical on-chain data.
CryptoQuant's proprietary PnL Index chart, which tracks Bitcoin's price against on-chain profitability metrics over a decade, recently issued a sell signal similar to those in 2013, 2017, and 2021, each preceding significant corrections or consolidation. 
"We are likely past the bull cycle peak," Ju had warned, anticipating sideways or bearish movement for six to twelve months. However, Bitcoin's price has since risen 10% above his initial call, despite a recent 10% drop.
The comments come amid a volatile week in crypto markets. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44987075/why-bitcoin-reclaiming-92900-could-be-a-pivotal-moment-glassnode">Why Bitcoin Reclaiming $92,900 Could Be A Pivotal Moment: Glassnode</a>
Why It Matters: As of Thursday evening European time, Bitcoin is trading around $93,000, down about 1% on the day.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) is lower at $1,755, while XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) are showing modest declines or trading flat.
Ju emphasized that short-term market moves are increasingly driven by event-based reactions, referencing political developments—making them difficult to interpret with traditional on-chain cycle indicators. 
"My focus is on long-term supply and demand using on-chain data," he noted. "But in a market that reacts to every Trump comment, short-term price actions are much more event-driven."
He added that if Bitcoin reaches a new all-time high before Q4, he would be forced to reconsider prevailing cycle theories: "In that case, the permabulls were right. Up only."
Iliya Kalchev, an analyst at Nexo Dispatch, commented on broader market influences, stating, "Today's U.S. calendar includes initial jobless claims and existing home sales, key reads on labor market health and consumer confidence." 
He added that Friday's University of Michigan consumer sentiment index and Alphabet's earnings could further impact risk appetite amid trade policy uncertainty.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44986939/saros-to-deploy-dlmm-technology-on-solana-aiming-to-improve-defi-liquidity-and-reduce-systemic-risks">Saros To Deploy DLMM Technology On Solana, Aiming To Improve DeFi Liquidity And Reduce Systemic Risks</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$ETH

$SOL

$XRP

If Bitcoin Breaks $100K, This CEO Will 'Gladly Admit' Being Wrong About A Bear Market

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock ended 2024 on a high note with shares hitting all-time highs in December, helping boost the wealth of CEO Elon Musk. The start of 2025 has been anything but the same, <a href="https://www.benzinga.com/25/04/44963440/tesla-takedown-says-protests-are-working-hitting-ev-company-where-it-hurts-the-companys-bottom-line">with shares down</a> and Musk's wealth falling by more than $100 billion.
What Happened: Musk ended 2024 as the world's richest person <a href="https://www.benzinga.com/news/management/25/01/42771258/worlds-top-10-richest-people-gained-more-wealth-in-2024-than-costco-and-nikes-combined-valuation-how-elon-musk-warren-buffett-and-others-fared">worth an estimated </a>$432 billion. The Tesla CEO added $203 billion to his wealth in 2024 and was the first person in the world to hit the $400 billion milestone.
As <a href="https://www.benzinga.com/general/sports/24/12/42521401/elon-musk-is-so-rich-he-could-buy-every-mlb-nba-nfl-nhl-team-and-still-have-cash-left-over">Benzinga previously shared, </a>Musk's wealth in 2024 was so high that he was worth more than every MLB, NBA, NFL and NHL team combined.
Fast forward to April 2025 and Musk is now worth $310 billion, according to <a href="https://www.bloomberg.com/billionaires/">Bloomberg</a>. This represents a decline of $122 billion from where Musk began the year.
With a wealth of $310 billion, Musk is still significantly ahead of the other billionaires of the world.
Amazon founder Jeff Bezos ranks second with a wealth of $202 billion, losing $36.8 billion in wealth in 2025.
So what's crazy is that Musk is now worth more than the following figures combined:
<ul>
<li>Jeff Bezos (Amazon founder): $202 billion</li>
<li>Jensen Huang (NVIDIA co-founder): $90 billion</li>
<li>Mark Cuban (entrepreneur, NBA owner): $7.55 billion</li>
<li>Total: $299.55 billion</li>
</ul>
That's right, Musk is worth more than the three billionaires combined. In fact, you could add in Palantir CEO Alex Karp, who is worth $9.35 billion and still be under Musk's current wealth.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: Musk's wealth drop highlights the downfall of Tesla stock year-to-date in 2025. Shares hit new all-time highs in December and soared after Donald Trump won the 2024 presidential election.
Early in 2025, Tesla stock fell after Trump took office and Musk's role in the White House with the Department of Government Efficiency led to calls for boycotts against Tesla and protests at dealerships.
Tesla lost brand value and sales began slipping in Europe and other regions.
Tesla stock is now down 32.6% year-to-date in 2025. Musk remains a large shareholder in Tesla and the EV stock makes up a large portion of his wealth, along with stakes in X, SpaceX, xAI and other companies.
In 2021, Musk <a href="https://www.benzinga.com/news/23/01/30362822/elon-musk-wins-a-guinness-world-record-but-he-likely-wont-be-celebrating">set a Guinness World Record </a>for the largest one-year drop in his wealth, losing between $180 billion and $200 billion. The billionaire is currently on pace to break that record, but a turnaround of Tesla stock with several catalysts coming later this year could help keep Musk from breaking his own record.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44479393/warren-buffett-top-wealth-gainer-elon-musk-top-wealth-loser-in-2025-heres-how-much-billionaires-have-added-lost">Warren Buffett Top Wealth Gainer, Elon Musk Top Wealth Loser In 2025: Here&#8217;s How Much Billionaires Have Added, Lost</a></li>
</ul>
Image created using photos from Shutterstock.

Education

Management

TSLA

Elon Musk Is $122 Billion Poorer In 2025, And Still Richer Than Bezos, Huang, Cuban Combined

MaxLinear shares are trading lower. The company reported Q1 financial results.

Benchmark analyst David Williams reiterates MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) with a Buy and maintains $20 price target.

Benchmark Reiterates Buy on MaxLinear, Maintains $20 Price Target

Finland-based Nokia Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) stock is trading lower on Thursday after its first-quarter FY25 earnings.
The telecommunications <a target="_blank" href="https://www.nokia.com/about-us/news/releases/2025/04/24/nokia-corporation-interim-report-for-q1-2025/" rel="noreferrer noopener">major opened 2025 with mixed financial results,</a> with net sales sliding 3% year-over-year on a constant currency and portfolio-adjusted basis.
The Network Infrastructure segment posted an 11% rise, and Cloud and Network Services increased by 8%. Mobile Networks also edged up 2%, offering some resilience amid broader headwinds stemming from a tough comparison with the prior year's performance in Nokia Technologies.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44961625/fda-targets-synthetic-food-dyes-in-sweeping-nutrition-overhaul" rel="noreferrer noopener">Automakers Are Struggling With Tariffs And EV Competition, Say Analysts</a>
The company reported a huge drop in gross margins, down 820 basis points year-over-year to 42.3% on a comparable basis, driven by reduced revenues from Nokia Technologies and a 120 million euros ($136.57 million) charge related to contract settlements in Mobile Networks.
Operating margins also shrank to 3.6% on a comparable basis. Diluted earnings per share for the first-quarter came in at 0.03 euros ($0.034).
"Regarding the tariff situation, there could be some short-term disruption. We will continue to utilize the flexibility of our global manufacturing network to minimize impact of the evolving tariff landscape. Based on what we see today, we currently expect a 20 to 30 million euros impact to our comparable operating profit in the second quarter from the current tariffs," said President and CEO Justin Hotard.
Nokia reaffirmed its full-year outlook, maintaining a projected operating profit between 1.9 billion euros and 2.4 billion euros and a free cash flow conversion rate of 50% to 80%.
In other news, Nokia has deepened its collaboration with T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) through a <a target="_blank" href="https://www.nokia.com/about-us/news/releases/2025/04/24/nokia-lands-strategic-5g-ran-deal-with-t-mobile-us-to-enhance-nationwide-connectivity/" rel="noreferrer noopener">new agreement focused on enhancing</a> and extending 5G services nationwide.
Nokia will provide a range of advanced solutions from its AirScale Radio Access Network lineup to elevate the Un-carrier's connectivity reach and performance.
The partnership involves rolling out Nokia's Habrok Massive MIMO antennas and Levante baseband platforms, both driven by the company's energy-efficient ReefShark chip technology.
These systems are designed to boost the network's performance, stability, and data speeds while minimizing power usage. Additionally, AI-driven solutions such as MantaRay SON and AutoPilot will help streamline and enhance T-Mobile's network's operational efficiency.
T-Mobile's network now covers over 332 million people and two million square miles, and Nokia has been its trusted RAN partner for many years.
Price Action: NOK shares traded lower by 8.29% at $4.87 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44991419/nvidia-powers-next-gen-adaptive-digital-ai-agents-for-cisco-nasdaq-and-meta" target="_blank" rel="noreferrer noopener">Nvidia Powers Next-Gen Adaptive Digital AI Agents For Cisco, Nasdaq, And Meta</a></li>
</ul>
Photo via Shutterstock

Earnings

Guidance

Movers

Tech

General

TMUS

Why Is Finnish Telecom Giant Nokia Stock Plunging Thursday?

Nano Nuclear Energy shares are trading higher after the company announced it, along with the University of Illinois, received a Nuclear Regulatory Commission fuel qualification methodology approval for its KRONOS MMR energy system.

<a href="https://www.bloomberg.com/news/articles/2025-04-24/authentic-brands-group-weighs-rival-bid-for-guess">https://www.bloomberg.com/news/articles/2025-04-24/authentic-brands-group-weighs-rival-bid-for-guess</a>

'Authentic Brands Group Weighs Rival Bid For Guess?'- Bloomberg

Natural gas futures extended their relentless slide into a tenth consecutive session Thursday, marking the worst losing streak since October 2019, yet one veteran market strategist sees a sharp turnaround ahead <a href="https://www.benzinga.com/topic/donald-trump">if trade tensions ease.</a>
In a note shared Thursday, Ed Yardeni, president of Yardeni Research, said investors may be underestimating the underlying strength of U.S. natural gas demand, particularly from utilities and exporters of liquefied natural gas. 
&#8220;If tariffs subside, natural gas prices stand to bounce sharply," Yardeni said. 
<h1 class="wp-block-heading">Henry Hub Prices Touch 6-Month Lows Amid Tariff Uncertainty</h1>
The front-month Henry Hub natural gas contract — as broadly tracked by the United States Natural Gas Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) —&nbsp;traded at $2.90 per million British thermal units on Thursday, its lowest level in six months.
Prices earlier this week broke below the 200-day moving average, a technical occurrence unseen since September 2024, deepening the bearish sentiment gripping the market.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529-1024x528.png" alt="" class="wp-image-887310" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529-1536x792.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24141856/NG1_2025-04-24_20-18-44_31529.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The ongoing rout comes in the wake of escalating trade tensions, including China&#8217;s retaliatory 49% tariff on U.S. liquefied natural gas imports, first introduced at 15% on Feb. 10. 
The tit-for-tat response to tariffs from the Trump administration has shaken global demand forecasts and altered trade flows, analysts said.
Chinese imports of U.S. LNG have plummeted to zero in recent months, according to shipping data cited by <a href="https://www.nytimes.com/2025/04/18/business/china-us-lng-trump-tariffs.html#:~:text=use%20in%20China.-,L.N.G.,to%20buy%20inexpensive%20Russian%20gas.">The New York Times. </a>
<h1 class="wp-block-heading">Supply Grows, But So Does Demand</h1>
Despite falling prices, U.S. production remains on an upward trajectory. Since 2022, output has increased by 1.5 trillion cubic feet, while consumption grew by 1.0 trillion and exports rose 0.8 trillion. 
Yardeni said this dynamic has left inventories thin, with U.S. natural gas stocks about 10% below the five-year average for this time of year.
&#8220;U.S. production of natural gas has increased nicely in recent years, but U.S. consumption and exports of the fuel have grown even faster," he said.
Since 2022, U.S. production has grown by 1.5 trillion cubic feet, while domestic consumption rose by one trillion and exports jumped by 0.8 trillion cubic feet.
The tight balance has drawn down inventories, leaving natural gas stocks about 10% below their five-year average for this time of year.
Data from the Energy Information Administration supports his view. U.S. consumption is projected to rise 1.8% in 2025 to 92 billion cubic feet per day, while LNG exports are forecast to jump 19% to 14.2 billion cubic feet per day.
While the short-term outlook for natural gas prices remains clouded by tariffs and geopolitical tensions, tight inventories and robust global demand suggest the current slump may not last.
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44984872/gillette-parent-procter-gamble-slides-on-q3-sales-decline-lowered-outlook">Gillette And Tide Maker Procter &amp; Gamble Feels The Heat From Commodity And Forex Costs, Cuts Profit Outlook</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/sdf_qwe">sdf_qwe</a> via Shutterstock

Commodities

Natural Gas Hits 10-Day Losing Streak: Why Ed Yardeni Thinks 'Prices Stand To Bounce Sharply' From Here

RZLV

Rezolve AI shares are trading higher after the company announced it has passed $50 billion in gross merchandise value in 2025.

Needham analyst David Saxon reiterates Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) from Hold to Hold.

BLCO

Needham Reiterates Hold on Bausch & Lombto Hold

Jones Trading analyst Jason Weaver reiterates PennyMac Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) from Hold to Hold.

Jones Trading Reiterates Hold on PennyMac Mortgage ITto Hold

AAOI

AKAM

ANET

CALX

COHR

DELL

FLEX

KEYS

LITE

MRIN

NTAP

NVTS

OKTA

PSTG

SNOW

TWLO

ZBRA

Shares of companies in the broader tech sector are trading higher amid overall market strength due to March's strong durable goods orders economic data, and President Trump's announcement that he met with China earlier today. Also, the industry may be moving up ahead of Alphabet's earnings report scheduled for after market close.

VTMX

Vesta shares are trading higher after the company reported a Q1 FFO beat.

Jones Trading analyst Jason Weaver reiterates ARMOUR Residential REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARR#NYSE">ARR</a>) from Hold to Hold.

Jones Trading Reiterates Hold on ARMOUR Residential REITto Hold

ALLY

ARES

Bakkt Holdings, Inc. Class A Common Stock

BKKT

COIN

FUTU

HOOD

HUIZ

IBKR

INTR

LPRO

SHF Holdings, Inc. - Class A Common Stock

SHFS

SOFI

STEP

TREE

TROW

UPST

Shares of companies within the broader financial sector are trading higher amid overall market strength due to March's strong durable goods orders economic data, and President Trump's announcement that he met with China earlier today.

Edwards Lifesciences&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares are trading higher Thursday after the company reported first-quarter 2025 sales of $1.41 billion.
That&#8217;s almost in line with the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $1.40 billion</a> and the management guidance of $1.35 billion—$1.43 billion, up 6.2% year-over-year or <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">7.9% on an adjusted basis</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry</a>
In the first quarter, the company reported: 
<ul>
<li>An adjusted EPS of 64 cents. It beat the consensus of 60 cents and remained within the management <a href="https://www.benzinga.com/general/health-care/25/02/43672055/heart-devices-focused-edwards-lifesciences-confident-in-2025-outlook-analyst-sees-long-term-strength" target="_blank" rel="noreferrer noopener">guidance of 58-64 cents</a>.</li>
<li>Transcatheter Aortic Valve Replacement (TAVR) sales of $1.05 billion. That&#8217;s up 3.8% (+5.4% on a constant currency basis, or <a href="https://www.benzinga.com/pressreleases/25/04/b44964740/edwards-lifesciences-reports-first-quarter-results" target="_blank" rel="noreferrer noopener">6.5% further adjusted)</a>.</li>
<li>Transcatheter Mitral and Tricuspid Therapies (TMTT) first-quarter sales were $115 million, representing growth of 58% year-over-year or more than 60% on a constant currency basis. </li>
<li>In Surgical, first-quarter global sales of $251 million increased 1% over the prior year, or 3% on a constant currency basis.</li>
</ul>
Guidance:&nbsp;Edwards Lifesciences expects second quarter 2025 adjusted EPS of 59-65 cents versus the consensus of 62 cents and revenue of $1.45 billion-$1.53 billion compared to the consensus of $1.46 billion.
The company reaffirmed the fiscal year 2025 adjusted EPS guidance of $2.40-$2.50, compared to the consensus of $2.46, and adjusted operating margins of 27%-28%.
Edwards on Thursday raised its 2025 TMTT sales guidance to $530 to $550 million, from $500 million to $530 million, driven by more favorable foreign exchange and continued business momentum.
The company, TAVR, and Surgical sales growth guidance ranges remain unchanged.
However, on Thursday, the company increased its original total company sales dollar guidance range by $100 million to account for the recent movement in FX rates. Edwards now expects total company sales of $5.7 to $6.1 billion, up from prior guidance of $5.60 billion—$6 billion compared to the consensus of $5.81 billion.
Piper Sandler upgraded Edwards Lifesciences stock, citing a better pathway back to double-digit growth in FY2026.
Analyst Adam C. Maeder writes, &#8220;While shares have traded reasonably well YTD on a relative basis (-5% vs. -8% for S&amp;P 500), EW remains a highly debated name amongst the investment community. We concede our upgrade call could be a bit on the early side.&#8221;
Piper Sandler upgraded the stock from Neutral to Overweight with a price <a target="_blank" href="https://www.benzinga.com/quote/EW/analyst-ratings" rel="noreferrer noopener">target raise from $73 to $80</a>.
&#8220;We also like EW&#8217;s positioning in an uncertain macro environment, namely, the company has little elective procedure exposure, no capex revenue, and a manageable anticipated tariff impact,&#8221; analyst Maeder adds.
Regarding macro/tariffs, William Blair writes that foreign exchange still hurt sales by 1.5% this quarter, but that was about 2% better than expected. The company now expects FX to have no impact on 2025 sales, changing from a previous forecast of a 2.5% drag.
As for tariffs, even though most U.S. supply comes from the company&#8217;s Irvine facility, the 5 cent hit to earnings per share comes from imports out of Singapore, Costa Rica, and, to a lesser extent, Europe.
Baird maintains Edwards Lifesciences with a Neutral, raising the price target from $72 to $75.
Price Action: EW stock is up 6.66% at $75.15 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44982328/american-airlines-flies-into-uncertainty-q1-revenue-miss-2025-outlook-pulled-but-debt-plan-on-track" target="_blank" rel="noreferrer noopener">American Airlines Flies Into Uncertainty: Q1 Revenue Miss, 2025 Outlook Pulled, But Debt Plan On Track</a></li>
</ul>
Image: Shutterstock

Analyst Color

Upgrades

Health Care

Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens

Press Releases

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Penny Stocks

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Biotech

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Comments

Allarity Therapeutics

Allarity Therapeutics (ALLR) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL